Subclinical Inflammation

Objectives: To evaluate the anti-inflammatory effects of sitagliptin in type 2diabetic hyperlipidemic patients. Period: 25 August 2015 to 25 November 2015 (12 weeks).Study Design: Randomized clinical trials. Setting: Outdoor of diabetic clinic of Sheikh ZayedMedical College/Hospital, Rahim Yar Khan. Materials and Methods: Diabetic patients (n=46)with poor glycemic control(HbA1c > 7.2%) and deranged lipid profile were selected. The patientreceived sitagliptin 50mg twice daily for 12 weeks. Results: A total of 46 patients completed thestudy. After 12 weeks treatment with sitagliptin, there was a significant reduction in the value ofHbA1c from 8.26±0.73% at baseline to 7.33±0.62% (p <0.01). Body mass index also decreasedsignificantly from 31.90±1.57 kg/m2 at baseline to 27.31±1.60 kg/m2 at 12 weeks (p<0.01).There was also significant reduction in the serum level of total Cholesterol (TC), triglycerides(TG) and Low density lipoprotein cholesterol( LDL-C) were detected( TC: 255.35±13.89to 220.76±14.65 mg/dl, TG: 188.80±11.62 to 153.39±9.24 mg/dl,; LDL-C 169.89±12.06 to147.11±8.1 mg/dl with p-value <0.01. High density lipoprotein cholesterol (HDL-C) increasedsignificantly from 41.21±3.11 mg/dl at baseline to 50.21±2.37 mg/dl (p <0.01) at 12 weeks.There is also significant reduction in the value of inflammatory markers after 12 weeks treatmentwith sitagliptin, ESR: 27.04±4.07 vs 11.43±1.74 mm/hr, WBC count: 6.90±0.51 vs 5.65±0.34109/L and hs-CRP: 4.21±0.37 vs 2.16±0.23 mg/L with p-value <0.01. Conclusion: Seeing themultiple benefits of sitagliptin on risk factors and markers of inflammation it is concluded that itshould be started early in diabetic patients to prevent micro and macro vascular complicationsin future.